Atossa Therapeutics Seeks Shareholder Approval for Further Stock Consolidation

Atossa Therapeutics calls a May 2026 shareholder vote to authorize a new reverse stock split, aiming to meet Nasdaq's price rules after a recent 15-for-1 consolidation.

Atossa Therapeutics is taking proactive measures to maintain its listing on the Nasdaq exchange. The biopharmaceutical company has scheduled a virtual Annual Meeting of Shareholders for May 7, 2026, where investors will vote on a critical proposal to authorize a reverse stock split. This move comes just weeks after the firm executed a previous consolidation, highlighting ongoing challenges with its share price compliance.

Shareholder Vote to Determine Nasdaq Fate

The central agenda item for the upcoming meeting is a request to grant the board of directors broad authority to implement a reverse stock split at a ratio ranging from 2-for-1 up to 20-for-1. Management positions this as a necessary contingency plan to elevate the company's stock price above the minimum bid requirement mandated by Nasdaq listing rules. The outcome of this vote is pivotal; without it, Atossa risks being delisted from the regulated exchange and moved to an over-the-counter market.

This request follows a recent and substantial consolidation. The company completed a 15-for-1 reverse split on February 2, 2026. The need to seek authorization for another potential consolidation so shortly afterward underscores the persistent pressure on the stock's market value. As of March 19, 2026, Atossa had approximately 8.6 million shares outstanding.

Financial Forecasts and Operational Costs

Amid these structural concerns, near-term financial expectations have also shifted. Analysts at HC Wainwright have revised their first-quarter 2026 loss per share estimate downward. They now project a loss of $1.34 per share, a deeper deficit than their previous forecast of a $1.20 per share loss.

On a positive operational note, the company achieved some cost efficiencies. Audit fees for the fiscal year 2025 decreased to about $697,000, compared to over $784,000 the year prior. However, the financial burden remains significant due to the ongoing clinical development costs for its lead breast cancer drug candidate, (Z)-Endoxifen.

Management Incentives and Path Forward

In a move to ensure management continuity, Chief Financial Officer Daniel Mark James was recently granted 63,000 Restricted Stock Units (RSUs). These equity awards are scheduled to vest over a three-year period, with the first tranche having vested at the end of March 2026.

The weeks leading to the May 7 shareholder decision will be crucial. Investors must weigh the necessity of preserving the Nasdaq listing against further share consolidation. The board's request for flexible authority reflects a strategic effort to safeguard the company's standing on a major exchange while it continues its clinical work.